How should PCNA be assessed? Total of stained cells or only the most intensely stained ones?
Keywords:
Breast Cancer, Prognostic Factor, Proliferating cell nuclear antigen (PCNA/cyclin)Abstract
OBJECTIVE: This study aimed to analyse whether a marker of proliferative activity (PCNA) could provide a prognosis of tumor evolution and to determine whether different interpretation criteria could alter the results. METHOD: The presence of PCNA in 59 patients of state II (T2 NO,1 MO) mammary carcinoma was determined. RESULT: Numerical proportions of total and intensely stained cells were established. These data were compared with anatomopathological parameters. A significant association between higher cyclin values and worse histological and nuclear grading was encountered, particularly in patients with a "negative axilla" using the PCNA index. Cyclin values were not significant in relation to any parameters when indices from the intensely stained cells were considered exclusively. CONCLUSION: Higher nuclear (NG3) and histological (HGIII) grading, associated with a high PCNA index (>50), distinguish high-risk patients, and it is more appropriate considering all the stained cells as representative of PCNA indices, thus reflecting tumor aggressiveness.
Downloads
References
Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-33.
Celis EJ, Celis A. Cell-cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S-phase. Proc Natl Acad Sci 1985; 82: 3262- 6.
Bravo R, Frank R, Blundell APP, Macdonad-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-d. Nature 1987; 326:515-17.
Garcia RL, Coltrera MD, Gown AM. Analysis of Proliferative Grade Using Anti-PCNA/Cyclin Monoclonal Antibodies in Fixed, Embedded Tissues. Am J Pathol 1989; 134: 733-39.
Hall AP, Levison AD, Woods LA, Yu WCC, Kellock BD, Watkins AJ, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-94.
Dawlson AE, Norton JA, Weinberg DS. Comparative assessment of proliferations and DNA content in breast carcinoma by image analysis and flow cytometry. AJP 1990; 136: 1115-24.
Shrestha P, Yamada K, Wada T, Maeda S, Watatani M, Yasutomi M, et al. Proliferating cell nuclear antigen in breast lesions: correlation of c-erb B-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Archiv A Pathol Anat 1992; 421: 193-202.
Aaltomaa S, Lipponen P, Papinaho S, Syrjanen K. Proliferating cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Rev Clin Oncol 1993; 119: 288-94.
Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic value of proliferating cell nuclear antigen in lymph node - negative breast cancer patients. Cancer 1993; 72: 120-5.
Cummings CM, Furnival MC, Parsons GP, Townsend E. PCNA immunostaining in breast cancer. Aust NZJ Surg. 1993; 63: 630-6.
Narita T, Fünahashi H, Satoh Y, Takagi H. Proliferation cell nuclear antigen immunostaining in breast cancer and its relation to prognosis. Jpm J Clin Oncol 1993; 23(1): 20-5.
Tahan RS, Neuberg SD, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-9.
Sullivan RP, Mortimer G, Muircheartaigh IO. Cell proliferations in breast tumor: analysis of histological parameters Ki-67 and PCNA expression. IJMS 1993; 162: 343-7.
Thomas M, Noguchi M, Kitagawa H, Kinoshija K, Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 1993; 46: 525-8.
Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-9.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181- 7.
World Health Organization. Histological typing of breast tumors. 2nd.ed.Geneva: WHO; 1981:106.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
Hsu S, Raine L, Fanger H. Use for Avidin-biotin- peroxidase comparison between ABC and unlabelled antibody PAP procedures. J Histochem Cytochem 1981; 29: 557-80.
Siegel S. Estadistica no parametrica. México: Trillas; 1975: 346.
Leonardi E, Girlando S, Serio G, Mauri AF, Perrone G, Scampini S, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 416-9.
Siitonen SM, Kallioniemi O, Isola JJ - Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. AJP 1993; 142: 1081-9.
Haerslav T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas: an immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Archiv 1994; 424: 39-46.
Fisher B, Redmond C, Fisher E, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol 1988; 6: 1076-87.
